Appointment dossier — Serous Carcinomas
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Serous Carcinomas
Compounds named in the cited literature for Serous Carcinomas, labeled by the strongest evidence found:
- prophylactic oophorectomy — Named in the literature
- recombinant REG4 protein — Named in the literature
- risk-reducing salpingectomy with delayed oophorectomy — Named in the literature
- risk-reducing salpingo-oophorectomy — Named in the literature
Open recruiting trials (18)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT06526819 · Phase 1 / Phase 2 — SMP-3124LP in Adults With Advanced Solid Tumors (United States)
- NCT07115043 · Phase 1 / Phase 2 — A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (United States)
- NCT05579366 · Phase 1 / Phase 2 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (United States)
- NCT05150691 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (United States)
- NCT06799065 · Phase 1 — First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer (United States)
- NCT06451497 · Phase 1 — This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (United States)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT06617897 · Phase 3 — Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (United Kingdom)
- NCT05601700 · Phase 3 — Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (Italy)
- NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
- NCT02491099 · Phase 2 — A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (United States)
- NCT06207305 · Phase 1 / Phase 2 — A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma (United States)
- NCT07480954 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (China)
- NCT04518501 · Phase 1 / Phase 2 — Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer (China)
- NCT05872204 · Phase 2 — Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (Belgium)
- NCT06639074 · Phase 2 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (United States)
Most-relevant first: trials that name Serous Carcinomas, then broader trials you may still qualify for. 67 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT05902988), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?